Security Health Plan releases new updates to prior authorizations and post service claim edits

Security Health Plan requires prior authorization (PA) and post service claim edits (PSCE) on medications in order to ensure coverage and payment for those services. Several requirements have been added for 2024 as we work to make sure all care, services and treatments are medically necessary. These drugs will be reviewed for medical necessity by Magellan.

As of April 1, 2024, Magellan will implement additional PAs and PSCEs for the following drugs given in-office or outpatient settings:

- Pemrydi rtu® (pemetrexed)
- Adzynma® (adamts13, recombinant-krhn)
- Omvoh® (mirikizumab-mrkz)
- Loqtorzi ® (toripalimab-tpzi)
- Casgevy® (exagamglogene autotemcel)
- Lyfgenia® (lovotibeglogene autotemcel)
- Avzivi® (bevacizumab-tnjn)
- Ryzneuta® (efbemalenograstim alfa-vuxw)
- Alyglo® (immune globulin intravenous, human-stwk)

This is only the list of new prior authorizations and post service claim edits required of members and providers to ensure payment for services. To review the full list of all medications that will require a prior authorization and/or post service claim edit, visit https://www.securityhealth.org/providers/medical-pharmacy. If you have any questions, please contact Security Health Plan Provider Relations at **1-800-548-1224**